ClinicalTrials.gg
RecruitingNCT07440537Updated Jun 8, 2026

Evaluate the Efficacy and Safety of ICP-488 in Subjects With Cutaneous Lupus Erythematosus (CLE) Double-blind Study

A Phase 2 interventional study of ICP-488 Tablets and ICP-488 Tablets in Cutaneous Lupus Erythematosus (CLE), sponsored by Beijing InnoCare Pharma Tech Co., Ltd.. Recruiting at 27 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-08.

Sponsored by Beijing InnoCare Pharma Tech Co., Ltd. (part of InnoCare Pharma Limited) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
105
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Lupus Erythematosus, Cutaneous with a site in China — 7 open to participants now, 10 under way, 5 of them phase 3. Lupus Erythematosus, Cutaneous · China.

Planned enrollment
9th of 12
105 · median 202
Started
2026
with 4 others
Phase 2
5 of 12
2 open now
Registered
10th of 12
by date
Lead sponsor
1 of 12
Beijing InnoCare Pharma Tech Co., Ltd.

Among the 12 studies in Lupus Erythematosus, Cutaneous with a site in China, this one is the 9th largest by planned enrollment, is one of 5 that started in 2026, is one of 5 in phase 2, and was the 10th registered.

Lupus Erythematosus, Cutaneous

67 studies on the registry are indexed under Lupus Erythematosus, Cutaneous; 18 are open to participants now.

Browse Lupus Erythematosus, Cutaneous studies →

Open to participants now

7 of the 12 studies in Lupus Erythematosus, Cutaneous with a site in China are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 12 Lupus Erythematosus, Cutaneous studies recruiting now, 4 (33%) set no upper age limit and 7 (58%) stop at 75 or younger; 2 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Lupus Erythematosus, Cutaneous with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical study to evaluate the efficacy and safety of ICP-488 in subjects with cutaneous lupus erythematosus (CLE).

03

Conditions studied

  • Cutaneous Lupus Erythematosus (CLE)
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged ≥18 and ≤75 years.
  2. Diagnosed with cutaneous lupus erythematosus (CLE) for at least 3 months before the screening visit.
  3. -proven histologically consistent with discoid lupus erythematosus (DLE) and/or subacute cutaneous lupus erythematosus (SCLE).
  4. CLASI activity (CLASI-A) score ≥8 at both the screening and baseline (Day 1) visits.
  5. May have concomitant systemic lupus erythematosus (SLE) or not.
  6. The treatment regimen is stable and can be maintained until the end of the study treatment.
  7. Women of (WOCBP) must have a negative serum pregnancy test result at screening and a negative urine pregnancy test result before the first dose on Day 1.
  8. Women of childbearing potential (WOCBP) and male subjects must agree to use highly effective methods throughout the study treatment period and for one month (28 days) after the last dose

Exclusion criteria

Exclusion Criteria:

  1. Specific cutaneous lupus erythematosus subtypes: acute cutaneous lupus erythematosus (ACLE), tumid lupus, lupus panniculitis (deep lupus), chilblain lupus.
  2. Patients with drug-induced cutaneous lupus erythematosus and/or drug-induced systemic lupus erythematosus.
  3. Subjects with active kidney disease 4.Other inflammatory joint or skin diseases or overlap syndrome not caused by systemic lupus erythematosus (SLE) as the primary disease.

5. Other diseases except for secondary Sjögren's syndrome. 6. Concurrent herpes zoster infection at screening or before dosing on Day 1, or a history of severe herpes zoster or severe herpes simplex infection.

7. Positive surface Antigen (HBsAg) at screening; or abnormal Hepatitis B Virus (HBV)Deoxyribonucleic Acid (DNA) Polymerase Chain Reaction (PCR) test result in subjects positive for Hepatitis B core Antibody (HBcAb).

8 Evidence of active, latent, or inadequately treated mycobacterium tuberculosis (TB) infection.

9.Previous or current use of other immunomodulatory or treatments except for permitted background medications specified in the protocol.

10. Inadequate organ function levels, including abnormalities in hematology, liver function, renal function, coagulation function, cardiac function, etc.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
105 participants (estimated)

Study arms

  • Experimental
    ICP-488 Dose A

    Drug: ICP-488 Tablets

  • Experimental
    ICP-488 Dose B

    Drug: ICP-488 Tablets

  • Placebo comparator
    ICP-488 Placebo

    Other: ICP-488 Placebo

Interventions

  • Patients will receive ICP-488 orally as per the protocol

  • Patients will receive ICP-488 orally as per the protocol

  • OtherICP-488 Placebo

    Patients will receive ICP-488 Placebo orally as per the protocol.

06

What researchers measure

Primary outcomes

  1. The percentage change of Cutaneous lupus erythematosus disease area and severity index-activity(CLASI-A) relative to the baseline at week 16.

    Time frame: All the subjects completed the 16-week assessment.

Secondary outcomes

  1. At each visit, the proportion of subjects whose CLASI-A score improved by ≥50% compared to the baseline value (CLASI-50).

    Time frame: From baseline to week 28

  2. The proportion of subjects with disease improvement as defined by a reduction of ≥4 points relative to the baseline value of CLASI-A (CLASI ≥ 4)at each visit.

    Time frame: From baseline to week 28

  3. The average change of the CLASI-A score from the baseline value at each visit.

    Time frame: From baseline to week 28

  4. The percentage change of CLASI-A relative to the baseline at each visit.

    Time frame: From baseline to week 28

  5. Adverse events that occurred during treatment.

    Time frame: From baseline to week 28

  6. The incidence of clinical abnormalities such as laboratory test results, electrocardiogram (ECG), and vital signs, and the changes relative to the baseline.

    Time frame: From baseline to week 28

  7. Maximum Concentration at Steady State(Cmax,ss)

    Time frame: From baseline to week 12

  8. Steady-State Time to Maximum

    Time frame: From baseline to week 12

  9. Area under the curve (AUC)

    Time frame: From baseline to week 12

07

Study locations

10 of 27 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2026 (actual). Primary completion is estimated for Mar 2027, 11 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2026
First posted
Feb 27, 2026
StartActual
Apr 27, 2026
Primary completionEst.
Mar 2027
CompletionEst.
Dec 2027
Last update
Jun 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07440537
Responsible party
Sponsor
First posted
Feb 27, 2026
Start date
Apr 27, 2026
Primary completion
Mar 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Jun 8, 2026

Study contacts

Alexia Lu
Contact
CO_HGRAC@innocarepharma.com
010-66609745

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ICP-488

Start the discussion